TW
Therapeutic Areas
Celularity Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CYCART-19 (CYNK-101) | Gastric, Gastroesophageal Junction Cancer | Phase 1 |
| CYNK-001 | Acute Myeloid Leukemia (AML), Multiple Myeloma | Phase 1 |
| CYNK-GDT | Glioblastoma Multiforme (GBM) | Preclinical |
| MLASC Platform | Degenerative Diseases (e.g., Osteoarthritis) | Preclinical |
| Biovance® | Diabetic Foot Ulcers, Surgical Reconstruction | Commercial |
| Interfyl® | Musculoskeletal Soft Tissue Repair | Commercial |
| Biovance® 3L | Complex Wounds | Commercial |
Leadership Team at Celularity
RJ
Robert J. Hariri
Chairperson, Founder, and CEO
SB
Stephen Brigido
President, Degenerative Diseases
JH
John Haines
Global Manager and Chief Administrative Officer
AG
Anna Gosiewska
R&D, Degenerative Diseases
SK
Sharmila Koppisetti
Clinical Development Immunology & Drug Safety
CP
Carmine Palummo
Corporate Operations
PD
Peter Diamandis
Director
GS
Geoffrey Shiu Fei Ling
Director
DP
Diane Parks
Director
VL
Vincent LeVien
Director